Current location - Trademark Inquiry Complete Network - Trademark registration - Is China Resources Shuanghe Pharmaceutical a state-owned enterprise or a central enterprise?
Is China Resources Shuanghe Pharmaceutical a state-owned enterprise or a central enterprise?

China Resources Shuanghe Pharmaceutical is a state-owned enterprise.

China Resources Shuanghe Pharmaceutical Co., Ltd. has a glorious history of 84 years. It was founded in 1939 as a military pharmaceutical factory. It was born in the revolutionary base of Taihang Mountain and was known as Lihua Pharmaceutical Factory. It moved to Beijing with the army in 1949. , later changed its name to Beijing Pharmaceutical Factory, and developed into a large-scale state-owned chemical drug comprehensive preparation enterprise, laying the foundation for Beijing's modern chemical pharmaceutical industry; in 1997, it integrated high-quality assets to establish Shuanghe Pharmaceutical, which was listed on the Shanghai Stock Exchange. Through external expansion, it became a company based in Beijing and radiating across the country. Cross-regional group; in 2010, it became a subsidiary of China Resources Group, a Fortune 500 company. In 2012, it was renamed China Resources Shuanghe. It is now one of the business units of China Resources Group in the field of health.

The company has 21 subsidiaries and more than 11,000 employees. Its main business covers new drug research and development, preparation production, drug sales, API production and pharmaceutical equipment. It has rich product lines and brand advantages. , high-quality product quality and cost control, strong channel and terminal coverage and management capabilities, international advantages, dynamic team advantages and profound cultural heritage, its economic strength, competitive vitality and sustainable development capabilities rank among the top domestic pharmaceutical companies . In 2022, it will achieve operating income of 9.447 billion yuan and net profit of 1.215 billion yuan.

The company actively deploys four major business platforms: generic drug business, infusion business, differentiated drug business and innovative drug business, and deeply develops in chronic diseases, infusion, pediatrics, nephrology, psychiatry/neurology and other fields, and enters the oncology Field, 18 key product years including No. 0, Fusuiyue, Nifedipine Sustained Release Tablets, Pitavastatin Calcium Tablets, Tangshiping, BFS Infusion, Clissol, Peritoneal Dialysis Solution, Magnesium Valproate Sustained Release Tablets, etc. Sales exceed 100 million yuan. It owns the well-known Chinese trademarks Shuanghe and Tusaike Xiangzhong, and has won many honors such as Top 100 Chinese chemical pharmaceutical companies.